The Asia Hub for e-Drug Discovery Symposium 2025 (AHeDD 2025) was successfully held in Xiaoshan, Hangzhou, from September 23 to 25. The self-developed, platform-based patented technology INTRAP®, showcased by Lleadart Biotechnologies made a substantial impact at the conference. As China's first biotech company to master breakthrough chemoproteomics, Lleadart positioned itself as a key innovator, inspiring new approaches to global drug design.
Innovative Technology Platform Reshaping the Drug Design Process
At the conference exhibition, Lleadart Biotechnologies' INTRAP® technology (In-Vivo Target Response Analysis Platform) attracted considerable attention from industry experts and attendees. Indeed, hailed as a "live-cell SPR" innovation, this technology is transforming the traditional rules of drug R&D.
The INTRAP® platform pairs specifically designed probes with quantitative detection technology to directly analyze drug-target interactions within live cells. This capability directly tackles a critical industry challenge: the frequent failure of in vitro efficacy to translate to in vivo results. The platform excels at studying complex membrane proteins such as VEGFR and GPCRs, offering novel solutions for traditionally difficult-to-drug targets.
Co-founder's In-Depth Presentation Highlights Technological Strength
During the conference, Dr. Yan Jie, Co-founder of Lleadart Biotechnologies, was invited to deliver a featured presentation titled "Chemoproteomics + Automation + AI: An Intracellular Ligand Discovery Platform." In it, he detailed how this integrated platform empowers new drug discovery. Drawing on over 15 years of drug development experience within US pharmaceutical companies, Dr. Yan shared the unique value of the INTRAP® platform in enhancing the efficiency and success rate of drug discovery.
Dr. Yan emphasized that the core trend in future drug design is shifting from experience-driven to data-driven and platform-based innovation. "The INTRAP® platform, which performs in-situ analysis within live cells, leverages automation and artificial intelligence to significantly shorten the drug discovery cycle and improve success rates," he stated in his presentation.From his perspective as a frontline practitioner, Dr. Yan clearly analyzed the core challenges in drug discovery. He explained how the INTRAP® platform synergistically combines innovative chemoproteomics, high-throughput automation, and advanced data algorithms, offering a novel and practical approach to tackling "undruggable" targets and enhancing early-stage efficiency.
QQ:
